Nausea

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

1100%

+ 36 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

13 programs

AprepitantPhase 4

MK0869, aprepitant / Duration of Treatment: 3 daysPhase 4

Standard POPhase 4

+8 more programs

Sharp TherapeuticsPA - Pittsburgh

13 programs

AprepitantPhase 41 trial

MK0869, aprepitant / Duration of Treatment: 3 daysPhase 41 trial

Standard POPhase 41 trial

+8 more programs

Active Trials

NCT00717054Completed115Est. Mar 2010

NCT00659737Completed115Est. Mar 2010

NCT00514878Completed2,000Est. Nov 2008

+10 more trials

ViiV HealthcareNC - Durham

1 program

OndansetronPhase 4

HelsinnIreland - Dublin

1 program

Fosaprepitant dimegluminePhase 31 trial

Active Trials

NCT01074697Completed246Est. Apr 2015

AstraZenecaCAMBRIDGE, United Kingdom

1 program

esomeprazolePhase 3Small Molecule1 trial

Active Trials

NCT00206440Terminated43Est. Feb 2012

Prevail TherapeuticsNY - New York

1 program

LY3537021Phase 21 trial

Active Trials

NCT07169851Recruiting204Est. Feb 2027

SandozAustria - Kundl

2 programs

Ondansetron HCl 24 mg TabletsPhase 11 trial

Active Trials

NCT00947128Completed26Est. Oct 2004

NCT00946387Completed26Est. Sep 2004

Merck & Co.RAHWAY, NJ

2 programs

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)N/A

MK0869, aprepitant / Duration of Treatment: 3 daysPHASE_3

Nielsen BioSciencesCA - San Diego

1 program

Sevoflurane-remifentanil anaesthesiaN/A1 trial

Active Trials

NCT00452855Completed160Est. May 2005

TakedaTOKYO, Japan

1 program

OndansetronPHASE_21 trial

Active Trials

NCT02006056Completed30Est. Jun 2014

GSKLONDON, United Kingdom

1 program

OndansetronPHASE_41 trial

Active Trials

NCT00429832Completed120Est. Nov 2005

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

Sharp TherapeuticsAprepitant

Sharp TherapeuticsMK0869, aprepitant / Duration of Treatment: 3 days

GSKOndansetron

Sharp TherapeuticsStandard PO

Sharp TherapeuticsMK0869, aprepitant / Duration of Treatment: 3 days

HelsinnFosaprepitant dimeglumine

AstraZenecaesomeprazole

Sharp TherapeuticsMK0869, aprepitant / Duration of Treatment: 3 days

Prevail TherapeuticsLY3537021

Sharp Therapeuticsaprepitant

TakedaOndansetron

Sharp TherapeuticsFosaprepitant dimeglumine

Sharp Therapeuticsaprepitant, ondansetron, dexamethasone

SandozOndansetron HCl 24 mg Tablets

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 6,242 patients across 21 trials

NCT00429754 Sharp TherapeuticsAprepitant

Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)

Est. completion: Sep 20080

Phase 4Withdrawn

NCT01636947 Sharp TherapeuticsAprepitant

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Start: Dec 2012Est. completion: Aug 2014494 patients

Phase 4Completed

NCT00090207 Sharp TherapeuticsMK0869, aprepitant / Duration of Treatment: 3 days

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Start: Jan 2004Est. completion: Sep 2004477 patients

Phase 4Completed

NCT00429832 GSKOndansetron

A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department

Start: Oct 2003Est. completion: Nov 2005120 patients

Phase 4Completed

NCT00781768 Sharp TherapeuticsStandard PO

Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea

Start: Aug 2003Est. completion: Jul 2010181 patients

Phase 4Completed

NCT00092183 Sharp TherapeuticsMK0869, aprepitant / Duration of Treatment: 3 days

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Start: Oct 2002Est. completion: Feb 2004866 patients

Phase 4Completed

NCT01074697 HelsinnFosaprepitant dimeglumine

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Start: Apr 2010Est. completion: Apr 2015246 patients

Phase 3Completed

NCT00206440 AstraZenecaesomeprazole

Nexium Study To Suppress Nausea During Chemotherapy

Start: Aug 2005Est. completion: Feb 201243 patients

Phase 3Terminated

NCT00092196 Sharp TherapeuticsMK0869, aprepitant / Duration of Treatment: 3 days

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Start: Dec 2002Est. completion: Dec 2004820 patients

Phase 3Completed

NCT07169851 Prevail TherapeuticsLY3537021

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Start: Nov 2025Est. completion: Feb 2027204 patients

Phase 2Recruiting

NCT01450826 Sharp Therapeuticsaprepitant

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Start: Jun 2014Est. completion: Apr 2017136 patients

Phase 2Completed

NCT02006056 TakedaOndansetron

Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting

Start: Nov 2013Est. completion: Jun 201430 patients

Phase 2Completed

NCT01405924 Sharp TherapeuticsFosaprepitant dimeglumine

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

Start: Oct 2011Est. completion: Dec 2013111 patients

Phase 2Terminated

NCT00711555 Sharp Therapeuticsaprepitant, ondansetron, dexamethasone

Emend for Multiple-day Emetogenic Chemotherapy

Start: Nov 2005Est. completion: Jan 200922 patients

Phase 2Completed

NCT00947128 SandozOndansetron HCl 24 mg Tablets

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

Start: Sep 2004Est. completion: Oct 200426 patients

Phase 1Completed

NCT00946387 SandozOndansetron HCl 24 mg Tablets

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions

Start: Sep 2004Est. completion: Sep 200426 patients

Phase 1Completed

NCT00835965 Sharp TherapeuticsDexamethasone

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

Start: Feb 200950 patients

N/AUnknown

NCT00659737 Sharp TherapeuticsAprepitant

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Start: Apr 2008Est. completion: Mar 2010115 patients

N/ACompleted

NCT00717054 Sharp TherapeuticsAprepitant

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Start: Feb 2008Est. completion: Mar 2010115 patients

N/ACompleted

NCT00514878 Sharp TherapeuticsDevelopment of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

Start: Aug 2007Est. completion: Nov 20082,000 patients

N/ACompleted

NCT00452855 Nielsen BioSciencesSevoflurane-remifentanil anaesthesia

Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea

Start: Jan 2002Est. completion: May 2005160 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 6,242 patients

12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.